NEW YORK and LONDON, November 5, 2015
Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced today that new data on Coversin efficacy in eculizumab resistant patients will be presented at the 57th American Society of Hematology (ASH) Annual Meeting taking place in Orlando from December 5-8. Coversin, Akari’s lead clinical product, is a second-generation complement inhibitor that acts on complement component-C5, preventing release of C5a and formation of C5b-9 (also known as the membrane attack complex or MAC).
